<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01935817</url>
  </required_header>
  <id_info>
    <org_study_id>unict11/1997</org_study_id>
    <nct_id>NCT01935817</nct_id>
  </id_info>
  <brief_title>Silybin - Vitamin E- Phospholipids Complex Reduces Liver Fibrosis in Patients With Chronic Hepatitis C Treated With Peg-IFN-a and RBV</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Catania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Catania</source>
  <brief_summary>
    <textblock>
      Chronic hepatitis C is both a virologic and a fibrotic disease, with mortality resulting
      mainly from the complications of cirrhosis and HCC.

      The investigators' aim will be to evaluate the impact on of supplementation with a new
      pharmaceutical complex of silybin-vitamin E-phospholipids in patients with chronic hepatitis
      C treated with Pegylated-Interferon-Î±2b plus Ribavirin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>transforming growth factor beta</measure>
    <time_frame>12 months</time_frame>
    <description>serum marker of liver fibrosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>hyaluronic acid</measure>
    <time_frame>12 months</time_frame>
    <description>serum marker of liver fibrosis</description>
  </secondary_outcome>
  <other_outcome>
    <measure>metalloproteinase 2</measure>
    <time_frame>12 months</time_frame>
    <description>serum marker of liver fibrosis</description>
  </other_outcome>
  <other_outcome>
    <measure>amino-terminal pro-peptide of type III procollagen</measure>
    <time_frame>12 months</time_frame>
    <description>serum marker of liver fibrosis</description>
  </other_outcome>
  <other_outcome>
    <measure>tissue inhibitor of matrix metalloproteinase type I</measure>
    <time_frame>12 months</time_frame>
    <description>serum marker of liver fibrosis</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Liver Fibrosis</condition>
  <arm_group>
    <arm_group_label>Silybin + vitamin E + phospholipids complex</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Silybin 94 mg + vitamin E 90 mg + phospholipids 194 mg in one pill per day for 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>one placebo pill per day for 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Silybin 94 mg + vitamin E 90 mg + phospholipids 194 mg complex</intervention_name>
    <arm_group_label>Silybin + vitamin E + phospholipids complex</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>sugar pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older,

          -  infection by HCV

          -  under treatment with pegylated interferon 2 alpha and ribavirin

        Exclusion Criteria:

          -  other liver diseases

          -  cancer

          -  severe jaundice

          -  pulmonary and renal chronic diseases

          -  prostatic diseases

          -  autoimmune diseases

          -  diabetes mellitus
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cannizzaro Hospital</name>
      <address>
        <city>Catania</city>
        <state>Sicily</state>
        <zip>95125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2013</study_first_submitted>
  <study_first_submitted_qc>September 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2013</study_first_posted>
  <last_update_submitted>September 4, 2013</last_update_submitted>
  <last_update_submitted_qc>September 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Catania</investigator_affiliation>
    <investigator_full_name>Mariano Malaguarnera</investigator_full_name>
    <investigator_title>A.P.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Tocopherols</mesh_term>
    <mesh_term>Tocotrienols</mesh_term>
    <mesh_term>alpha-Tocopherol</mesh_term>
    <mesh_term>Silybin</mesh_term>
    <mesh_term>Silymarin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

